Compare LUV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUV | RPRX |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 22.0B |
| IPO Year | 1995 | 2020 |
| Metric | LUV | RPRX |
|---|---|---|
| Price | $41.02 | $54.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $45.37 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 6.4M | 2.9M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.93% | 1.90% |
| EPS Growth | ★ 3.95 | N/A |
| EPS | 0.45 | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $16.57 | $38.63 |
| Revenue Next Year | $3.61 | $4.73 |
| P/E Ratio | $90.16 | ★ $79.72 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $28.98 | $32.21 |
| 52 Week High | $55.11 | $53.53 |
| Indicator | LUV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 73.44 |
| Support Level | $36.29 | $35.35 |
| Resistance Level | $42.76 | N/A |
| Average True Range (ATR) | 1.37 | 1.08 |
| MACD | 0.18 | 0.15 |
| Stochastic Oscillator | 72.09 | 98.66 |
Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates nearly 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated with a simple cabin configuration in a point-to-point network. In early 2026, Southwest modified its cabins to offer some rows with extra legroom, its ticketing process and merchandising to offer assigned seats, and more fare categories to include a basic economy class that appears for the first time in travel aggregators' search results and more directly competes with other airlines' offerings.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.